Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

NCT05037929 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05037929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2021
Completion date
July 7, 2025
Enrollment
1,334 (actual)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease